SGLT2 inhibitors with metformin do not increase fracture risk in diabetics
https://medicaldialogues.in/diabetes-endocrinology/news/sglt2-inhibitors-with-metformin-do-not-increase-fracture-risk-in-diabetics-study-68736
Combination therapy with SGLT2 inhibitors and metformin in patients with type 2 diabetes (T2D) does not increase fracture risk versus metformin monotherapy, according to a recent study in the journal Osteoporosis International.
According to the authors, no study has evaluated the association between sodium-glucose transporter-2 inhibitors (SGLT2is) and metformin use and fracture risk. Therefore the aim of this study by B-B. Qian, The Second Clinical College of Dalian Medical University, Yangzhou, Jiangsu, China, and colleagues was to investigate the fracture risk of SGLT2is and metformin combination therapy in T2D patients.
The researchers scrutinized online databases
for all eligible randomized controlled trials (RCTs). The summarized odds
ratios (ORs) and their 95% confidence intervals (CI) were calculated using
Review Manager 5.3 software.
A total of 25 RCTs involving 19,500 participants with T2D were included in this
study.
Key findings of the study include:
There were 88 fracture cases in the SGLT2is in combination with metformin therapy group and 79 in the control group.
SGLT2is combined with metformin use did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM.
After
stratification by drug type, follow-up time, control regimen, and type of
fracture, the upshots were still stable.
"The results of our meta-analysis manifested no detrimental effect of
SGLT2is combined with metformin therapy on fracture risk in T2DM patients. When
stratified by control regimen, drug type, follow-up duration, and type of
fracture, we still did not see a significant difference in the two sets of
results," wrote the authors.
"SGLT2is and metformin combination therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM," they concluded.
The study, "Association between
combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes
mellitus on fracture risk: a meta-analysis of randomized controlled
trials," is published in the journal Osteoporosis International.